Comparison of clinical efficacy and safety of weekly glucagon‐like peptide‐1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel‐group, multicentre, open‐label trial ( COMING study)
Diabetes, Obesity and Metabolism · 2023
DOI: 10.1111/dom.15258 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Tomohiko Kimura und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Kawasaki Medical School.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To compare the clinical usefulness of once‐weekly glucagon‐like peptide‐1 receptor agonists dulaglutide and semaglutide at the doses approved for use in Japanese patients with type 2 diabetes.
Methods
In total, 120 patients with glycated haemoglobin (HbA1c) ≥7% were randomly assigned to dulaglutide (n = 59) or semaglutide group (n = 61), and 107 participants (dulaglutide/semaglutide = 53/54) completed the 24‐week trial. The primary endpoint was the difference of HbA1c level between the two groups at 24 weeks.
Results
HbA1c level at 24 weeks was significantly lower in the semaglutide group (7.9 ± 0.5%‐6.7 ± 0.5%) compared with the dulaglutide group (8.1 ± 0.6%‐7.4 ± 0.8%) ( p < .0001). Reduction in body mass index and visceral fat area were also more significant in the semaglutide group ( p < .05, respectively). The achievement rate of HbA1c
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
- Department of Internal Medicine, Osugki Hospital, Takahashi, Japan.
- Department of General Internal Medicine 1, Kawasaki Medical School, Okayama, Japan.
- Department of Internal Medicine, Murakami Memorial Hospital, Onomichi, Japan.
- Department of Internal Medicine, Kurashiki Sweet Hospital, Kurashiki, Japan.
- Department of Diabetic Medicine, Kurashiki Central Hospital, Kurashiki, Japan.
ORCID-Profile: Tomohiko Kimura, Masashi Shimoda, Kohei Kaku
Förderung
- Kawasaki Medical School
Zitieren
APA
Kimura, T., Katakura, Y., Shimoda, M., Kawasaki, F., Yamabe, M., Tatsumi, F., Matsuki, M., Iwamoto, Y., Anno, T., Fushimi, Y., Kamei, S., Kimura, Y., Nakanishi, S., Mune, T., Kaku, K., Kaneto, H., & COMING study Group (2023). Comparison of clinical efficacy and safety of weekly glucagon‐like peptide‐1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel‐group, multicentre, open‐label trial ( COMING study). Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15258
Vancouver
Kimura T, Katakura Y, Shimoda M, Kawasaki F, Yamabe M, Tatsumi F, et al. Comparison of clinical efficacy and safety of weekly glucagon‐like peptide‐1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel‐group, multicentre, open‐label trial ( COMING study). Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15258
BibTeX
@article{Kimura2023,
author = {Kimura, Tomohiko and Katakura, Yukino and Shimoda, Masashi and Kawasaki, Fumiko and Yamabe, Mizuho and Tatsumi, Fuminori and Matsuki, Michihiro and Iwamoto, Yuichiro and Anno, Takatoshi and Fushimi, Yoshiro and Kamei, Shinji and Kimura, Yukiko and Nakanishi, Shuhei and Mune, Tomoatsu and Kaku, Kohei and Kaneto, Hideaki and COMING study Group, COMING study Group},
title = {Comparison of clinical efficacy and safety of weekly glucagon‐like peptide‐1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel‐group, multicentre, open‐label trial ( COMING study)},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
doi = {10.1111/dom.15258}
}
EUVIMED